Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Immunicum announces that a patent application in the USA regarding the Company's CD70-technology will be granted

Immunicum AB
Posted on: 14 Sep 16

Gothenburg, Sweden, September 14, 2016. Immunicum AB (publ), a biopharmaceutical company pursuing to developsophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the United States Patent and Trademark Office (USPTO) intends to grant a patent relating to the Company's CD70-technology.

- This further improves our already strong IP portfolio. The decision from the United States Patent and Trademark Office, USPTO, gives us important protection for our CD70-technology, says Jamal El-Mosleh, CEO of Immunicum.

The US patent to be granted, with the title "Method for proliferation of antigen-specific T cells", protects the method for expansion of tumor specific T cells for so called adoptive immunotherapy with CAR T cells.

For more information, please contact:
Jamal El-Mosleh, CEO, Immunicum
Ph: +46 (0) 31 41 50 52

About Immunicum AB (publ)
Immunicum AB (publ) develops cancer immune primers for the treatment of
tumor diseases. A phase II clinical trial for the Company's most advanced
product - INTUVAX ® against kidney cancer - has been initiated. The project
portfolio contains additional clinical phase I/II studies in liver cancer and in
gastrointestinal stromal tumors (GIST). Immunicum is listed on First North Premier.

The company's Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31

The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the company's contact person on September 14, 2016 at 14.00 CET.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Immunicum AB via GlobeNewswire

Last updated on: 15/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.